KMT2C Polyclonal antibody

KMT2C Polyclonal Antibody for WB, IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, IHC, IF, CoIP, ChIP, ELISA

Conjugate

Unconjugated

Cat no : 28437-1-AP

Synonyms

MLL3, Lysine N methyltransferase 2C, KIAA1506, Homologous to ALR protein, HALR



Tested Applications

Positive WB detected inK-562 cells
Positive IHC detected inhuman ovary cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunohistochemistry (IHC)IHC : 1:200-1:800
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

28437-1-AP targets KMT2C in WB, IHC, IF, CoIP, ChIP, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen KMT2C fusion protein Ag28875
Full Name myeloid/lymphoid or mixed-lineage leukemia 3
Calculated Molecular Weight 541 kDa
Observed Molecular Weight541kDa, 269 kDa
GenBank Accession NumberNM_170606
Gene Symbol KMT2C
Gene ID (NCBI) 58508
RRIDAB_2918165
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Lysine (K)-specific methyltransferase 2C (KMT2C, also known as MLL3) belongs to the mixed-lineage leukemia (MLL) family of histone methyltransferases which methylate the histone 3 tail at lysine 4 (H3K4) as part of the complex proteins associated with Set 1 (COMPASS) complex. Although originally identified as oncogenic fusions in leukemia, genome-wide mutation studies have revealed frequent, presumably loss-of-function, mutations in various members of the MLL family, including MLL2/KMT2B, MLL3/KMT2C, and MLL4/KMT2D in a variety of malignancies, particularly solid tumors. Mechanistic studies of KMT2C in normal cells have focused primarily on its role in enhancer regulation by deposition of H3K4me1 marks.

Protocols

Product Specific Protocols
WB protocol for KMT2C antibody 28437-1-APDownload protocol
IHC protocol for KMT2C antibody 28437-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Int Immunopharmacol

Polysaccharides from Platycodonis Radix ameliorated respiratory syncytial virus-induced epithelial cell apoptosis and inflammation through activation of miR-181a-mediated Hippo and SIRT1 pathways.

Authors - Juan-Juan Li
humanChIP

J Biol Chem

TRIM28 represses renal cell carcinoma cell proliferation by inhibiting TFE3/KDM6A-regulated autophagy

Authors - Tanjing Song
humanWB,IF,CoIP

Adv Sci (Weinh)

TAOK3 Facilitates Esophageal Squamous Cell Carcinoma Progression and Cisplatin Resistance Through Augmenting Autophagy Mediated by IRGM

Authors - Mingchuang Sun
humanWB

Nat Chem Biol

UFL1 triggers replication fork degradation by MRE11 in BRCA1/2-deficient cells

Authors - Tian Tian